Abzena Expands GMP Potency Testing

Abzena, a leading CDMO + CRO, has expanded its early and late-phase analytical services to include GMP cell-based potency assays at its Cambridge, UK, and San Diego, CA facilities. This addition enhances its bioassay offerings, enabling faster, more reliable data critical for biopharmaceutical development, including ADC cytotoxicity and GMP product release testing.

The move supports developers in optimizing strategies, meeting regulatory needs, and advancing drug programs efficiently. Abzena remains committed to delivering end-to-end analytical solutions to drive success from discovery through commercialization.